

MAMMAPRINT

At - A - Glance

Learn More...



High Risk or Low Risk

Only FDA cleared test
(to date) for risk assessment of
breast cancer metastasis within
5 years in women of all ages



70 Genes
More genes, more
information about your tumor

Results you can trust.
Clinical benefit shown in a
phase III, randomized trial



Covered by Medicare
and other insurance

REQUEST THE TEST

For more information, contact:



888.321.2732 Agendia Customer Care



customer@agendia.com

Join the Community. Follow us on:



www.KnowYourBreastCancer.com



facebook.com/symphonysisterhood



twitter.com/symphonysister

Watch our new patient video:



<http://knowyourbreastcancer.com/mammaprint-patient-video>



agendia
decoding cancer

Decoding cancer. One Patient at a time.

Personalized Medicine with MammaPrint



MammaPrint® can reveal the
genomic makeup of your
breast cancer

REQUEST THE TEST

Consult your physician to see if
MammaPrint is right for you.



The majority of women with early-stage breast cancer have a Low Risk of cancer recurrence, and may avoid chemotherapy.¹

MammaPrint is currently the only FDA cleared test for risk of recurrence within five years in women of all ages that provides a personalized high or low risk result. This result will help you and your doctor determine a treatment management plan.

What is genomic testing?

Genomic testing looks at specific genes in a tumor to find out what is driving its growth. This type of testing helps design a personalized medical treatment plan tailored to the patient's specific needs. Genomic tests are not the same as genetic tests. Genetic tests are used to determine your inherited risk or hereditary predisposition for cancer.

Your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer (ER, PR, or HER2). These factors, along with your tumor's genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.

What will the MammaPrint Test Results Show?

MammaPrint is a 70-gene test that will assess your cancer's risk of distant metastasis, in other words, how likely the cancer is to have spread to other parts of the body. You are given either a Low Risk or High Risk result, with no intermediate results (which can occur with similar type tests).

In patients with the most common type of breast cancer (hormone receptor positive, HER2 negative, lymph node negative) a Low Risk genomic test result showed a 97.8% chance of being metastasis free at 5 years with hormonal therapy alone. There was no significant benefit of adding chemotherapy for genomically Low Risk Patients.

Patients with a High Risk genomic test result and treated with hormonal therapy and chemotherapy, had a 94.6% chance of being metastasis free at 5 years. These results are based on the landmark MINDACT clinical trial and represent the average risk of recurrence for these two groups.¹

What if I am in the Low Risk group?

Consistent with the MINDACT trial, if you are Low Risk by the 70-gene test, you have a low risk of the cancer returning and there may be little to no benefit of undergoing chemotherapy treatment. Patients that were genomically Low Risk had an average of 2.2% risk of distant recurrence at 5 years on hormonal therapy alone.¹

What if I am in the High Risk group?

If you are High Risk by the genomic test, you have a higher risk of the cancer returning and studies have shown a 50% relative benefit of adding chemotherapy.² In the MINDACT trial, patients that were genomically High Risk had an average of 5.4% risk of recurrence at 5 years with chemotherapy in addition to hormonal therapy.¹

Will my insurance cover the test?

In the United States and Puerto Rico, Agendia is contracted with Medicare and many other large national and regional health plans. Agendia will bill your insurance company directly throughout the US. Based on your specific benefit level, your insurance company may choose to pay a portion or all of the cost of the tests run by Agendia. You will be responsible for any co-insurance, co-pay, or deductible expenditure per your health insurance plan terms.

Please give us a call and one of our dedicated Patient Advocates will work with you and your insurance company to find out your specific coverage details. Agendia's Patient Advocates can be reached at 888-363-7868 or by email at billing@agendia.com.

What if I don't have insurance or my health plan doesn't cover it?

Please contact Agendia's Patient Advocates at 888-363-7868 to inquire about programs offered by Agendia that may assist with patient access to our tests or to learn more about how Agendia can assist with an insurance appeal.

[1] Cardoso, F., et al. N Engl J Med 2016; 375: 717-29.

[2] Knauer, M., et al. Breast Cancer Res Treat, (Mar 2010) 120(3):655-661

